Download PDF
CC BY-NC-ND 4.0 · Dtsch Med Wochenschr 2022; 147(04): 179-186
DOI: 10.1055/a-1658-5176
Review

Moderne medikamentöse Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose

Modern drug therapy for systemic sclerosis associated interstitial lung disease
Martin Aringer
1   Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik III, Bereich Rheumatologie
,
Dirk Koschel
2   Fachkrankenhaus Coswig, Lungenzentrum, Abteilung Innere Medizin und Pneumologie
3   Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik I, Bereich Pneumologie
,
Andreas Krause
4   Immanuel Krankenhaus Berlin, Abteilung Rheumatologie, Klinische Immunologie und Osteologie
,
Udo Schneider
5   Charité – Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
,
Sven Gläser
6   Vivantes Klinikum Neukölln und Spandau Berlin, Klinik für Innere Medizin – Pneumologie und Infektiologie sowie Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B
› Author AffiliationsSupported by: Firma Boehringer Ingelheim Pharma GmbH & Co. KG
Supported by: Firma Infill Healthcare Communication GmbH
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die systemische Sklerose mit interstitieller Lungenerkrankung (SSc-ILD) ist mit einem erhöhten Morbiditäts- und Mortalitätsrisiko verknüpft. Da es an zugelassenen Medikamenten mangelt, die den Krankheitsverlauf einer SSc-ILD effektiv beeinflussen, besteht ein hoher Bedarf an neuen Therapieoptionen. Die Behandlung mit immunmodulierenden Therapien sowie der autologen Stammzelltransplantation wird in klinischen Studien aktuell weiter untersucht. Kürzlich belegte zudem eine Phase-III-Studie die positive Wirkung des antifibrotischen Wirkstoffs Nintedanib auf den Verlust an Lungenvolumen und somit die Krankheitsprogression bei Patienten mit SSc-ILD. Eine Kombinationstherapie aus Nintedanib und Mycophenolat könnte basierend auf synergistischen Wirkprinzipien zukünftig einen ergänzenden Behandlungsansatz der SSc-ILD darstellen.

Abstract

Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD) is associated with an increased risk of morbidity and mortality. Because of a lack of approved medications that can effectively influence SSc-ILD disease course, there is a need for new therapeutic options. Treatment with immunomodulatory therapies as well as with autologous stem cell transplant is being further investigated in current clinical studies. Recently, a phase III study demonstrated the positive effect of the antifibrotic agent nintedanib on the loss of lung volume and thus disease progression in patients with SSc-ILD. Due to its synergistic mechanism of action, combination therapy with nintedanib and mycophenolate could be a complementary treatment approach for SSc-ILD in the future.

Schlüsselwörter

Systemische Sklerose - Interstitielle Lungenerkrankung - Therapie

Key words

systemic sclerosis - interstitial lung disease - therapy


Publication History

Article published online:
03 December 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 2019; 20: 13
    CrossrefPubMedSearch in Google Scholar
  • 2 Denton CP, Khanna D. Systemic sclerosis. Lancet Lond Engl 2017; 390: 1685-1699
    CrossrefPubMedSearch in Google Scholar
  • 3 Khanna D, Tashkin DP, Denton CP. et al. Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease. Rheumatology 2019; 58: 567-579
    CrossrefPubMedSearch in Google Scholar
  • 4 Wollin L, Distler JH, Denton CP. et al. Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. J Scleroderma Relat Disord 2019; 4: 212-218
    CrossrefPubMedSearch in Google Scholar
  • 5 Takei R, Arita M, Kumagai S. et al. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. Respirology 2018; 23: 385-391
    CrossrefPubMedSearch in Google Scholar
  • 6 Winstone TA, Assayag D, Wilcox PG. et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014; 146: 422-436
    CrossrefPubMedSearch in Google Scholar
  • 7 Distler O, Highland KB, Gahlemann M. et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 2019; 380: 2518-2528
    CrossrefPubMedSearch in Google Scholar
  • 8 Perelas A, Silver RM, Arrossi AV. et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 2020; 8: 304-320
    CrossrefPubMedSearch in Google Scholar
  • 9 Hoffmann-Vold AM, Maher TM, Philpot EE. et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2020; 2: e71-e83
    CrossrefPubMedSearch in Google Scholar
  • 10 Kowal-Bielecka O, Fransen J, Avouac J. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76: 1327-1339
    CrossrefPubMedSearch in Google Scholar
  • 11 Tashkin DP, Elashoff R, Clements PJ. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666
    CrossrefPubMedSearch in Google Scholar
  • 12 Tashkin DP, Roth MD, Clements PJ. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708-719
    CrossrefPubMedSearch in Google Scholar
  • 13 Khanna D, Lin CJF, Furst DE. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020;
    CrossrefPubMedSearch in Google Scholar
  • 14 Sircar G, Goswami RP, Sircar D. et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatol Oxf Engl 2018; 57: 2106-2113
    CrossrefPubMedSearch in Google Scholar
  • 15 Benad M, Koschel D, Herrmann K. et al Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease. Clin Exp Rheumatol 2021
    PubMed
  • 16 Nadashkevich O, Davis P, Fritzler M. et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-212
    CrossrefPubMedSearch in Google Scholar
  • 17 Adler S, Huscher D. EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network. et al. Systemic sclerosis associated interstitial lung disease – individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther 2018; 20: 17
    CrossrefPubMedSearch in Google Scholar
  • 18 Allanore Y, Vonk MC, Azuma A. et al Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON. Arthritis Rheumatol 2020; 72 (Suppl. 10)
    PubMed
  • 19 Maher TM, Distler O, Allanore Y. et al. Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Beyond 52 Weeks: Data from the SENSCIS Trial. C22 ILD Ther III 2020; A4558-A4558
    CrossrefPubMedSearch in Google Scholar
  • 20 Highland K, Distler O, Kuwana M. et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: subgroup analysis of the SENSCIS trial. Lancet Respir Med 2020;
    CrossrefPubMedSearch in Google Scholar
  • 21 Goh N, Denton CP, Lynch DA. et al. Effect of Nintedanib in Patients with Limited and Extensive Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS Trial. A37 ILD Ther I 2020; A1525-A1525
    CrossrefPubMedSearch in Google Scholar
  • 22 Jouneau S, Lescoat A, Riemekasten G. et al Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Body Mass Index (BMI) at Baseline: Subgroup Analysis of the SENSCIS Trial | A37. ILD THERAPY I. Am J Respir Crit Care Med 2020; 2020201A1526. Im Internet (Stand: 20.07.2020): https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1526
    PubMed
  • 23 Lescoat A, Jouneau S, Crestani B. et al. Is the Rate of Lung Function Decline the Same in Patients with Systemic Sclerosis-Associated Ild (ssc-Ild) Who Experience Weight Loss? Data from the Senscis Trial. Ann Rheum Dis 2020; 79: 1110-1110
    CrossrefPubMedSearch in Google Scholar
  • 24 Riemekasten G, Carreira P, Saketkoo LA. et al. Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSC-ILD) and normal versus elevated C-reactive protein (CRP) at baseline: Analyses from the SENSCIS trial. Ann Rheum Dis 2020; 79: 413
    CrossrefPubMedSearch in Google Scholar
  • 25 Volkmann E, Vettori S, Varga J. et al. Is There a Difference Between the Sexes in the Rate of Progression of Systemic Sclerosis-Associated Ild (ssc-Ild)? Data from the Senscis Trial. Ann Rheum Dis 2020; 79: 1118-1119
    CrossrefPubMedSearch in Google Scholar
  • 26 Vonk MC, Distler O, Furst DE. et al Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use [abstract]. Arthritis Rheumatol 2019; 71 (Suppl. 10) 1643
    PubMedSearch in Google Scholar
  • 27 Flaherty KR, Wells AU, Cottin V. et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381: 1718-1727
    CrossrefPubMedSearch in Google Scholar
  • 28 Ebata S, Yoshizaki A, Oba K. et al. Lancet Rheumatology 2021; 3 (07) E489-E497
    CrossrefPubMedSearch in Google Scholar